Athenex (ATNX) Given News Impact Score of 0.13
Headlines about Athenex (NASDAQ:ATNX) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Athenex earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.583248671587 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Athenex (ATNX) traded down 1.18% during midday trading on Monday, hitting $14.24. The stock had a trading volume of 61,819 shares. The stock’s 50-day moving average is $16.86 and its 200-day moving average is $16.86. The company’s market capitalization is $579.37 million. Athenex has a 1-year low of $11.21 and a 1-year high of $20.79.
Separately, Deutsche Bank AG initiated coverage on Athenex in a research note on Monday, July 10th. They issued a “buy” rating and a $20.00 target price for the company.
In related news, Director Song-Yi Zhang purchased 328,637 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was bought at an average price of $11.00 per share, for a total transaction of $3,615,007.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $44,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johnson Yiu Nam Lau purchased 25,200 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was bought at an average price of $11.00 per share, with a total value of $277,200.00. Following the transaction, the chief executive officer now owns 2,722,722 shares of the company’s stock, valued at approximately $29,949,942. The disclosure for this purchase can be found here.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.